Reposted by Katerina Stankova
Evolutionary therapy (ET) needs accurate tumour burden tracking.
"RECIST misses disease progression by months and ET must be guided by 3D measurements"
@katstankova.bsky.social @tpmtudelft.bsky.social @erasmusmc.bsky.social #erasmus #cancerevolution
doi.org/10.1093/jeb/...
doi.org
Enabling evolutionary therapy in metastatic cancer lacking serum biomarkers
Abstract. Evolutionary therapy (ET) aims to anticipate and steer tumour evolution by adjusting treatment timing and dosing, often to control rather than er